ASC22

anti-PD-L1 monoclonal antibody · Ascletis Pharmaceuticals Co., Ltd.

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for ASC22, covering 2022-09-19 to 2024-12-02. Get the full timeline:

Most recent: Clinical Trial Update: A Phase II Study of Subcutaneously Injected PD-L1 Antibody ASC22 in Chronic Hepatitis B Patients [Phase 2]